Nika Pharmaceuticals, Inc financial data

Industry
Miscellaneous Transportation Equipment
Location
2269 Merrimack Valley Avenue, Henderson, Nevada
State of incorporation
Colorado
Fiscal year end
December 31
Former names
CENTENNIAL GROWTH EQUITIES INC (to 8/15/2022)
Latest financial report
Q1 2024 - May 28, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 15.7 % -38.1%
Debt-to-equity -119 % +11.4%
Return On Equity 99.7 % -99.6%
Return On Assets -536 % +99.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.02B shares
Common Stock, Shares, Outstanding 876M shares 0%
Entity Public Float 0 USD
Common Stock, Value, Issued 87.6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 876M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 876M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
General and Administrative Expense 111K USD +137%
Operating Income (Loss) -111K USD +96.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -111K USD +96.5%
Net Income (Loss) Attributable to Parent -111K USD +96.5%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.5K USD +449%
Inventory, Net 17K USD
Assets, Current 41.5K USD +830%
Assets 41.5K USD +830%
Accounts Payable, Current 1.5K USD
Liabilities, Current 266K USD +543%
Liabilities 266K USD +543%
Retained Earnings (Accumulated Deficit) -8.93M USD -166%
Stockholders' Equity Attributable to Parent -224K USD -509%
Liabilities and Equity 41.5K USD +830%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -150K USD -667%
Net Cash Provided by (Used in) Financing Activities 155K USD +569%
Common Stock, Shares Authorized 2.7B shares 0%
Common Stock, Shares, Issued 876M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.87K USD +35.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.5K USD +449%
Deferred Tax Assets, Valuation Allowance 714K USD +2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 714K USD +2%
Preferred Stock, Shares Issued 10M shares 0%
Preferred Stock, Shares Authorized 15M shares +50%
Additional Paid in Capital 8.62M USD +167%
Preferred Stock, Shares Outstanding 10M shares 0%
Current Federal Tax Expense (Benefit) -14K USD +97.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%